JP2017500849A5 - - Google Patents

Download PDF

Info

Publication number
JP2017500849A5
JP2017500849A5 JP2016534133A JP2016534133A JP2017500849A5 JP 2017500849 A5 JP2017500849 A5 JP 2017500849A5 JP 2016534133 A JP2016534133 A JP 2016534133A JP 2016534133 A JP2016534133 A JP 2016534133A JP 2017500849 A5 JP2017500849 A5 JP 2017500849A5
Authority
JP
Japan
Prior art keywords
seq
peptide
transport
moiety
cargo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016534133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500849A (ja
JP6932506B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066619 external-priority patent/WO2015080943A1/en
Publication of JP2017500849A publication Critical patent/JP2017500849A/ja
Publication of JP2017500849A5 publication Critical patent/JP2017500849A5/ja
Application granted granted Critical
Publication of JP6932506B2 publication Critical patent/JP6932506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016534133A 2013-11-26 2014-11-20 細胞透過組成物およびそれを用いる方法 Active JP6932506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908963P 2013-11-26 2013-11-26
US61/908,963 2013-11-26
PCT/US2014/066619 WO2015080943A1 (en) 2013-11-26 2014-11-20 Novel cell-penetrating compositions and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020001263A Division JP2020072716A (ja) 2013-11-26 2020-01-08 細胞透過組成物およびそれを用いる方法

Publications (3)

Publication Number Publication Date
JP2017500849A JP2017500849A (ja) 2017-01-12
JP2017500849A5 true JP2017500849A5 (https=) 2017-12-28
JP6932506B2 JP6932506B2 (ja) 2021-09-08

Family

ID=53199565

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016534133A Active JP6932506B2 (ja) 2013-11-26 2014-11-20 細胞透過組成物およびそれを用いる方法
JP2020001263A Pending JP2020072716A (ja) 2013-11-26 2020-01-08 細胞透過組成物およびそれを用いる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020001263A Pending JP2020072716A (ja) 2013-11-26 2020-01-08 細胞透過組成物およびそれを用いる方法

Country Status (5)

Country Link
US (2) US9908915B2 (https=)
EP (1) EP3074049B1 (https=)
JP (2) JP6932506B2 (https=)
ES (1) ES2806027T3 (https=)
WO (1) WO2015080943A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110201144B (zh) 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
WO2021158317A1 (en) * 2020-02-07 2021-08-12 The Reasearch Foundation For Suny Methods for preventing and reversing opioid analgesic tolerance in subjects with chronic pain

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US5004688A (en) 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
CA2389236A1 (en) 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020077283A1 (en) * 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AU2003207744A1 (en) 2002-01-30 2003-09-02 Yale University Transport peptides and uses therefor
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7250398B2 (en) 2003-09-12 2007-07-31 Novozymes A/S Synthetic antimicrobial polypeptides
CN101511181B (zh) * 2006-07-11 2013-08-21 新泽西医科和牙科大学 蛋白、编码该蛋白的核酸和相关的应用方法
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US8309034B2 (en) * 2007-06-09 2012-11-13 Honeywell International Inc. Compositions, methods and devices for control and clean-up of hazardous spills
WO2009079692A1 (en) * 2007-12-21 2009-07-02 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
US11260133B2 (en) 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
JP5859307B2 (ja) 2008-09-10 2016-02-10 ジェネンテック, インコーポレイテッド 眼の血管新生を阻害する方法
WO2013184482A1 (en) 2012-06-04 2013-12-12 Yale University Method of treating and preventing ocular angiogenesis
WO2015080980A2 (en) * 2013-11-26 2015-06-04 E&B Technologies Llc Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators

Similar Documents

Publication Publication Date Title
ES2484796T3 (es) Compuestos de GLP-1 extendidos
JP2014520120A5 (https=)
DK2760463T3 (en) REGULATION OF SODIUM CHANNELS USING PLUNC PROTEINS
US20110256130A1 (en) Methods of treating inflammatory disorders
WO2020156513A1 (zh) 双配体药物偶联体及其用途
JP2016501204A5 (https=)
JP2009521908A5 (https=)
JP2016512213A5 (https=)
JP2011526886A5 (https=)
JP2012505902A5 (https=)
JP7846169B2 (ja) 細胞透過性ペプチド
JP2010508305A5 (https=)
JP2014525901A5 (https=)
JP2015522264A5 (https=)
BRPI0607762A2 (pt) anÁlogo de glp-1, mÉtodo para aumentar o tempo de aÇço em um paciente de um anÁlogo de glp-1, composiÇço farmacÊutica, e, uso de um composto
JP2011508785A5 (https=)
KR101993937B1 (ko) 염증 억제용 펩티드
JP2017500849A5 (https=)
US10632187B2 (en) Hemagglutinin-binding peptide
EP2766384B1 (en) Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
JP2021523945A5 (https=)
JP2023521999A (ja) 修飾ミニヌクレオソームコアタンパク質及び核酸送達における使用
JP2019038772A5 (https=)
JP2006523608A5 (https=)
JP2005506276A5 (https=)